Prosecution Insights
Last updated: April 19, 2026

Examiner: MARTIN, RACHEL E

Tech Center 1700 • Art Units: 1651 1657 1682 1792

This examiner grants 55% of resolved cases

Performance Statistics

55.0%
Allow Rate
-10.0% vs TC avg
104
Total Applications
+54.2%
Interview Lift
1178
Avg Prosecution Days
Based on 60 resolved cases, 2023–2026

Rejection Statute Breakdown

10.7%
§101 Eligibility
14.0%
§102 Novelty
37.0%
§103 Obviousness
32.7%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17769452 METHOD FOR EVALUATING DRUG TOXICITY Non-Final OA Takeda Pharmaceutical Company Limited
18516616 VARIANTS OF A DNA POLYMERASE OF THE POLX FAMILY Non-Final OA Centre National De La Recherche Scientifique
17742035 PRODUCTION METHOD FOR LIPID PARTICLES IN LIQUID AND METHOD FOR CULTURING MICROORGANISMS Final Rejection KANEKA CORPORATION
18250645 MUTANT PROTEASES AND USES THEREOF Non-Final OA BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
18681047 METHOD FOR PRODUCTION OF AMMONIA, USING INORGANIC NANOPARTICLE-MICROBIAL COMPLEX Non-Final OA KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY
17597304 SERPIN PRODUCTION Non-Final OA SOCIETE DES PRODUITS NESTLE S.A.
18546449 UPCYCLING OF PLASTIC WASTE TO RECOMBINANT SILK PROTEINS VIA PSEUDOMONAS BACTERIA Non-Final OA Rensselaer Polytechnic Institute
18110973 METHOD FOR PRODUCING ORGANIC SUBSTANCE Final Rejection SEKISUI CHEMICAL CO., LTD.
17603978 CATALYTICALLY INACTIVE BOTULINUM NEUROTOXIN-LIKE TOXINS AND USES THEREOF Non-Final OA Children's Medical Center Corporation
17570104 FUSION PROTEIN NANODISK COMPOSITIONS AND METHODS OF TREATMENT Final Rejection The Brigham and Women's Hospital, Inc.
17641586 BIOFILM TRANSFORMATION Non-Final OA Oxford University Innovation Limited
18573419 RECOMBINANT MICROORGANISM IN WHICH EXPRESSION OF NADH:QUINONE OXIDOREDUCTASE IS CONTROLLED, AND METHOD FOR PRODUCING O-PHOSPHOSERINE, CYSTEINE, AND DERIVATIVE THEREOF BY USING SAME Non-Final OA CJ CHEILJEDANG CORPORATION
17480792 METHOD FOR PRODUCING ALLOLACTOSE Final Rejection AJINOMOTO CO., INC.
18844679 A NOVEL PROTEIN COMPOSITION AND THEIR USE IN FORMULATING DAIRY PRODUCTS Non-Final OA PHYX44 LABS PRIVATE LIMITED
18277398 METHOD FOR PRODUCING A HYDROXYTYROSOL Final Rejection Wacker Chemie AG
18392498 Reducing or Inhibiting Ocular Damage by Hyaluronidase Administration Non-Final OA Med Progress, LLC
17311262 COMPOSITIONS FOR STABILIZING BACTERIA AND USES THEREOF Final Rejection Seres Therapeutics, Inc.
17594994 METHODS FOR THE FRACTIONATION OF PROTEINS Final Rejection THE UNIVERSITY OF SYDNEY
18561525 REDOX SENSITIVE CRALBP MUTANT PROTEINS Non-Final OA UNIVERSITÄT BERN
18578921 Phytase Variants Non-Final OA AB Enzymes Oy
18551182 MODIFIED HOST CELLS FOR HIGH EFFICIENCY PRODUCTION OF VANILLIN Non-Final OA AMYRIS , INC.
18575597 ENHANCED EXPRESSION OF AN AROMATIC AMINO ACID DECARBOXYLASE (AADC) IN THE SUBSTANTIA NIGRA FOR THE TREATMENT OF PARKINSON'S DISEASE Non-Final OA Comell University
18398273 RECOMBINANT PROTEIN CAPABLE OF RESISTING MULTIPLE SCLEROSIS AND PREPARATION METHOD AND APPLICATION THEREOF Non-Final OA INSTITUTE OF ZOOLOGY, GUANGDONG ACADEMY OF SCIENCES
17799190 SPRAY FREEZE DRYING OF STRICT ANAEROBIC BACTERIA Final Rejection Chr. Hansen A/S
18569824 COMPOSITIONS AND METHODS FOR MICROBIAL TREATMENT OF SKIN DISORDERS Non-Final OA IFF US Holding, LLC
18279596 A METHOD FOR PREPARATION OF alpha-GLUCAN Non-Final OA Xiaolin Li
17294587 MICROFLUIDIC IN VITRO MODEL FOR ELUCIDATING THE MOLECULAR EFFECTS OF SIMULATED DIETARY REGIMENS ON GUT MICROBIOTA AND HOST CELLS Non-Final OA Universite Du Luxembourg
17610249 POLYPEPTIDES FOR TREATMENT OF BACTERIAL INFECTIONS Non-Final OA CC Biotech Ltd.
18010092 ENGINEERED MAD7 DIRECTED ENDONUCLEASE Final Rejection BIO-TECHNE CORPORATION
17907572 SPERMIDINE-SUPPLEMENTED FOOD PRODUCTS Non-Final OA KALIN HEALTH LLC

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month